argus

Zydus Lifesciences Limited

NSE: ZYDUSLIFEINE010B010271,16,952 Cr

Timeline

Time (IST)TypeMEventSrc
25 Mar, 04:18 pmZydus Lifesciences Limited has informed the Exchange about General Updatesnse
21 Mar, 08:16 amZydus Lifesciences Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Zydus launches Semaglutide Injection in an innovative, reusable multi-dose pen device in India".nse
21 Mar, 08:12 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
19 Mar, 09:30 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
19 Mar, 09:27 amZydus Lifesciences Limited has informed the Exchange regarding a press release dated March 19, 2026, titled "Zydus launches Aerolife Mini , to simplify inhaler use for asthma and COPD patients".nse
18 Mar, 03:11 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
18 Mar, 03:08 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated March 18, 2026, titled "Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India".nse
17 Mar, 12:00 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
17 Mar, 12:00 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated March 17, 2026, titled "Zydus and Lupin sign licensing agreement for co-marketing innovative Semaglutide Injection in India".nse
16 Mar, 08:15 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
16 Mar, 08:15 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Sentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome".nse
14 Mar, 01:42 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
14 Mar, 01:39 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated March 14, 2026, titled "Zydus new drug discovery, Desidustat licensed to China Medical System Holdings receives approval from NMPA of China".nse
13 Mar, 10:05 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
13 Mar, 10:02 amZydus Lifesciences Limited has informed the Exchange regarding a press release dated March 13, 2026, titled "Zydus receives final approval from USFDA for Cevimeline Hydrochloride Capsules 30mg".nse
12 Mar, 02:24 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
12 Mar, 02:21 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated March 12, 2026, titled "Zydus expands companion diagnostics portfolio with the launch of AI-powered Continuous Glucose Monitor DiasensTM and GlucoLiveTM".nse
28 Feb, 11:16 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
28 Feb, 11:13 amZydus Lifesciences Limited has informed the Exchange regarding a press release dated February 28, 2026, titled "Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg".nse
27 Feb, 02:54 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
27 Feb, 02:50 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated February 27, 2026, titled "Zydus Lifesciences announces successful clinical development of Pembrolizumab biosimilar FYB206, marking a milestone toward USFDA filing".nse
25 Feb, 06:51 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
25 Feb, 06:48 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated February 25, 2026, titled "Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry, expanding patient access to GLP-1 therapy".nse
19 Feb, 08:41 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated February 19, 2026, titled "Closure of USFDAinspection at Zydus Injectable plant at Ahmedabad".nse
19 Feb, 08:39 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
19 Feb, 09:50 amZydus Lifesciences Limited has informed the Exchange regarding a press release dated February 19, 2026, titled "Zydus launches biosimilar Aflibercept 2 mg ANYRA for advancing ophthalmic care ".nse
19 Feb, 09:47 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
18 Feb, 06:10 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
18 Feb, 06:07 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated February 18, 2026, titled "Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg".nse
17 Feb, 10:21 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
17 Feb, 10:18 amZydus Lifesciences Limited has informed the Exchange regarding a press release dated February 17, 2026, titled "Zydus launches PEPAIR, a first in India, affordable, drug-free, handheld device for better respiratory health".nse
15 Feb, 07:20 pmZydus Lifesciences Limited has informed the Exchange about Transcriptnse
15 Feb, 07:17 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
14 Feb, 11:14 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
14 Feb, 10:09 amZydus Lifesciences Limited has informed the Exchange regarding a press release dated February 14, 2026, titled "Zydus receives final approval from USFDA for Ammonium Lactate Cream, 12%".nse
12 Feb, 08:26 amZydus Lifesciences Limited has informed the Exchange about General Updatesnse
12 Feb, 08:26 amZydus Lifesciences Ltd - 532321 - Update On Litigationbse
10 Feb, 05:52 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
10 Feb, 05:48 pmZydus Lifesciences Limited has informed the Exchange about Link of Recordingnse
09 Feb, 01:31 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated February 09, 2026, titled "Press Release".nse
09 Feb, 01:30 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
09 Feb, 01:27 pmZydus Lifesciences Limited has informed the Exchange about Investor Presentationnse
09 Feb, 01:26 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
09 Feb, 01:23 pmZydus Lifesciences Limited has informed the Exchange regarding 'Board comments on penalties levied by BSE and NSE'.nse
09 Feb, 01:22 pmZydus Lifesciences Ltd - 532321 - Unaudited Financial Results For The Quarter And Nine Months Ended On December 31, 2025bse
09 Feb, 01:20 pmZydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.nse
09 Feb, 01:19 pmZydus Lifesciences Ltd - 532321 - Board Meeting Outcome for Unaudited Financial Results For The Quarter And Nine Months Ended On December 31, 2025bse
06 Feb, 12:21 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
06 Feb, 12:18 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of Sickle Cell Disease".nse
04 Feb, 02:40 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse